Wipro Appoints Anne-Marie Rowland as CEO of Capco
Wipro (NYSE: WIT, BSE: 507685, NSE: WIPRO), a leading technology services and consulting company, today announced that Anne-Marie (“Annie”) Rowland has been appointed to the role of Capco’s Chief Executive Officer. Rowland is currently Managing Partner of Capco’s business in the United Kingdom and Ireland and a member of Capco’s Global Leadership Team. She will take on the CEO role effective April 1, 2024.
As CEO of Capco, Rowland will report to Wipro CEO and Managing Director Thierry Delaporte and will become a member of Wipro’s Executive Committee (WEC).
Lance Levy, who has led Capco as CEO for close to a decade, will take on a new role as Strategic Advisor and continue to support Capco’s strategic direction and Wipro’s overall Consulting strategy.
“Lance has provided unmatched leadership to Capco for over a decade. Under his guidance, Capco has differentiated itself as an industry-leading full-service transformation consultancy, and become a key growth pillar for Wipro,” said Delaporte. “I’m glad to announce Lance’s continued support as Strategic Advisor, helping Annie and Capco’s business through a carefully planned transition. Annie has a deep understanding of Capco, our clients, teams, and the Consulting industry. I’m proud to welcome Annie to lead Capco into the future, to its next phase of growth.”
Rowland joined Capco 14 years ago and has deep Consulting expertise in business change management, innovation, and transformation.
Since joining Capco, Rowland has played a pivotal role in the growth of Capco’s business through a series of executive roles, having served on the Capco Global Leadership Team for several years in a number of capacities, including as Global Head of Capco’s Consulting and Transformation practice, Global Client Partner for a number of large financial institutions, Executive Sponsor of Women@Capco and most recently as the Managing Partner for Capco’s UK and Ireland business. Rowland was recognized by Consulting Magazine for the Global Women Leaders in Consulting Award in 2021.
Commenting on the appointment, Lance Levy, Capco’s current Chief Executive Officer, said, “Capco is an incredibly special business, and I am honored to have led the company, and very grateful to all of those who have played such an important part in the company’s founding and growth, and especially our people, who work tirelessly in fulfilling our commitment to innovation and transformational outcomes for our clients.
“I am incredibly proud of all we have achieved together, and we have continued to raise the bar in terms of our creativity, focus on innovation, domain expertise and the solutions that we have provided to our clients. I have seen at first hand Annie’s huge contribution to the success of our business and the satisfaction of our clients, and I know under her leadership we are opening a new chapter in Capco’s growth story. I look forward to continuing to work closely with both Annie and Thierry in my new role as Strategic Advisor.”
Capco, acquired by Wipro in 2021, has been a trusted client advisor and industry player for over 25 years, evolving from a niche service provider to become the world’s largest, independent, financial services management consultancy. Capco combines deep domain expertise, a disruptive mindset, and a proven track record of delivering lasting value to solve clients’ most complex transformational challenges.
“I am delighted about the opportunity to lead Capco into the next phase of its journey,” said Annie Rowland, Capco’s incoming Chief Executive Officer. “As a long-time Capco veteran, I am committed to preserving all that makes Capco special: our client relationships, our unique and authentic culture, and our focus on innovation and creativity.
“Our clients’ needs are changing at pace as they look to meet the challenges and opportunities presented by emerging technology and evolving business landscapes. Together, Capco and Wipro are a winning combination that delivers the deep expertise, focus and scale required to ensure our clients’ future success. I am delighted to be taking the helm of such a remarkable company, and I want to thank Lance for his exceptional leadership and guidance over the years, and I know we will continue to work closely together as he moves forward in his new role.”
About Wipro
Wipro Limited (NYSE: WIT, BSE: 507685, NSE: WIPRO) is a leading technology services and consulting company focused on building innovative solutions that address clients’ most complex digital transformation needs. Leveraging our holistic portfolio of capabilities in consulting, design, engineering, and operations, we help clients realize their boldest ambitions and build future-ready, sustainable businesses. With over 240,000 employees and business partners across 65 countries, we deliver on the promise of helping our customers, colleagues, and communities thrive in an ever-changing world. For additional information, visit us at www.wipro.com.
About Capco
Capco, a Wipro company, is a global technology and management consultancy focused on the financial services and energy industries. Capco operates at the intersection of business and technology by combining innovative thinking with unrivalled industry knowledge to fast-track digital initiatives for banking and payments, capital markets, wealth and asset management, insurance, and the energy sector. Capco’s cutting-edge ingenuity is brought to life through its award-winning Be Yourself At Work culture and diverse talent. To learn more, visit www.capco.com or follow us on LinkedIn, Instagram, Facebook, and YouTube.
Forward-Looking Statements
The forward-looking statements contained herein represent Wipro’s beliefs regarding future events, many of which are by their nature, inherently uncertain and outside Wipro’s control. Such statements include, but are not limited to, statements regarding Wipro’s growth prospects, its future financial operating results, and its plans, expectations and intentions. Wipro cautions readers that the forward-looking statements contained herein are subject to risks and uncertainties that could cause actual results to differ materially from the results anticipated by such statements. Such risks and uncertainties include, but are not limited to, risks and uncertainties regarding fluctuations in our earnings, revenue and profits, our ability to generate and manage growth, complete proposed corporate actions, intense competition in IT services, our ability to maintain our cost advantage, wage increases in India, our ability to attract and retain highly skilled professionals, time and cost overruns on fixed-price, fixed-time frame contracts, client concentration, restrictions on immigration, our ability to manage our international operations, reduced demand for technology in our key focus areas, disruptions in telecommunication networks, our ability to successfully complete and integrate potential acquisitions, liability for damages on our service contracts, the success of the companies in which we make strategic investments, withdrawal of fiscal governmental incentives, political instability, war, legal restrictions on raising capital or acquiring companies outside India, unauthorized use of our intellectual property and general economic conditions affecting our business and industry.
Additional risks that could affect our future operating results are more fully described in our filings with the United States Securities and Exchange Commission, including, but not limited to, Annual Reports on Form 20-F. These filings are available at www.sec.gov. We may, from time to time, make additional written and oral forward-looking statements, including statements contained in the company’s filings with the Securities and Exchange Commission and our reports to shareholders. We do not undertake to update any forward-looking statement that may be made from time to time by us or on our behalf and our reports to shareholders. We do not undertake to update any forward-looking statement that may be made from time to time by us or on our behalf.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240320633322/en/
Contact information
Media contact:
Media-relations@wipro.com
tim.steele@capco.com
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Axelspace: Notice of Signing a Service contract for In-Orbit Demonstration with Pale Blue, Inc.22.12.2025 10:00:00 CET | Press Release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” has entered into a service agreement with Pale Blue Inc. (“Pale Blue”), a company that develops, manufactures, and sells thrusters (engines) for small satellites, for an in-orbit demonstration, as detailed below. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219321165/en/ Jun Asakawa, Co-founder & CEO of Pale Blue (left in photo) and Yuya Nakamura, President and CEO of Axelspace Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Under this contract, an in-orbit demonstration of a fast-start Hall thruster developed by Pale Blue is scheduled to be conducted in 2027. Nonetheless, conducting in-orbit demonstrations in a short period of time is known to be a significant challenge due to the in
Axelspace Signing Agreement on a Multi-Launch Arrangement and the Launch of New Satellites with Exolaunch22.12.2025 10:00:00 CET | Press Release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” is pleased to announce a multi-launch agreement (MLA) with Exolaunch, a global launch integrator and leader in launch mission management, satellite integration and satellite deployment technologies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219038364/en/ The Multi-Launch Agreement will accelerate the growth of Axelspace. In particular, one satellite scheduled for launch under the new Agreement will be used in the AxelLiner business’s in-orbit demonstration service, “AxelLiner Laboratory”. Exolaunch has already secured launches for eight (8) Axelspace’s satellites on the upcoming missions. Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Nonetheless, conducting in-orbit demonstration
Zambon Biotech Announces First Patient Dosed in Phase 3b ADIP Clinical Study of IPX203 in Parkinson’s Disease22.12.2025 10:00:00 CET | Press Release
Zambon Biotech, a specialized biotech company part of the Zambon group that aims to build a scientifically robust and commercially viable portfolio of innovative patient-oriented drugs through the scouting, acquisition, licensing and development of new molecules, today announced that the first participant with advanced Parkinson’s disease has been enrolled in the European Phase 3b ADIP (IPX203 in Advanced Parkinson’s disease) study, which is planned to evaluate the efficacy and safety of IPX203 versus immediate-release (IR) levodopa/carbidopa (LD/CD) in a regimen which has not yet been the focus of a Phase 3 trial. IPX203 is a novel, oral modified-release formulation of LD/CD designed for the treatment of Parkinson’s disease, the fastest growing neurological condition in the world according to the World Health Organization1. IPX203 contains immediate-release granules and extended-release beads, providing both a rapid onset of action and a longer duration of benefit, sustaining the levo
Pimicotinib Approved as Systemic Treatment in China for Tenosynovial Giant Cell Tumor22.12.2025 09:00:00 CET | Press Release
Merck, a leading science and technology company, announced today that following Priority Review, the China National Medical Products Administration (NMPA) has approved pimicotinib for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will potentially cause functional limitation or relatively severe morbidity. Pimicotinib, a colony stimulating factor-1 receptor (CSF-1R) inhibitor developed by Abbisko Therapeutics Co., Ltd., Shanghai, China, is the first Chemical Drug Class 1 approved in China for the treatment of TGCT. “We are continuing to deliver on our commitment to improving the lives of patients with rare tumors with this first-in-the-world regulatory approval of pimicotinib,” said Danny Bar-Zohar, CEO Healthcare and Member of the Executive Board of Merck. “This approval is a significant step forward in further strengthening our leadership in rare tumors, while offering patients the opportunity to change the course of
Incyte Japan Announces Approval of Minjuvi ® (tafasitamab) in Combination with Rituximab and Lenalidomide for the Treatment of Relapsed or Refractory Follicular Lymphoma22.12.2025 08:44:00 CET | Press Release
Incyte Biosciences Japan G.K. today announced approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for Minjuvi® (tafasitamab) in combination with rituximab and lenalidomide for adult patients with relapsed or refractory follicular lymphoma (2L+ FL). “Today's approval of Minjuvi in combination with rituximab and lenalidomide marks a significant milestone as the first dual-targeted CD19 and CD20 immunotherapy combination for relapsed or refractory FL in Japan,” said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. “By improving progression-free survival, Minjuvi offers a chemotherapy-free option for eligible patients with relapsed or refractory disease. This approval underscores our commitment to bridging critical treatment gaps to patients and families affected by this challenging disease in Japan.” The approval is based on the pivotal Phase 3 inMIND trial, which enrolled 654 adult patients, including patients based in Japan. The study demonstrated that Minjuvi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom